Caraway
acquired by Merck3 known investors
Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases. Acquired by Merck in 2023.
Investors · 3
Frequently asked questions
- What does Caraway do?
- Caraway Therapeutics was a preclinical biopharmaceutical company developing small-molecule therapies modulating lysosomal function to treat neurodegenerative and rare diseases. Acquired by Merck in 2023.
- Who are Caraway's investors?
- Caraway's investors include Eisai Innovation, Inc., MRL Ventures Fund, SV Health Investors.
- Who acquired Caraway?
- Caraway was acquired by Merck.